文献速递甲状腺核医学肿瘤 PET/CT

[18F]FAPI-42 PET/CT在分化型甲状腺癌中的应用:诊断效能、摄取值及与2-[18F]FDG PET/CT的比较

[18F]FAPI-42 PET/CT in differentiated thyroid cancer: diagnostic performance, uptake values, and comparison with 2-[18F]FDG PET/CT.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-12-10

本研究纳入42例Tg或抗Tg抗体生化升高的分化型甲状腺癌(DTC)患者行[18F]FAPI-42 PET/CT,其中11例7天内另行2-[18F]FDG PET/CT。27例(64%)患者共检出161个病灶;[18F]FAPI-42 PET/CT诊断效能与2-[18F]FDG PET/CT相当。

要点

  • 27例(64%)患者经[18F]FAPI-42 PET/CT检出161个病灶。
  • 局部复发灶FAPI摄取最高,肺病灶最低(平均SUVmax 4.7 vs 2.2)。
  • 双模态均阳性的90个病灶中2-[18F]FDG摄取总体高于[18F]FAPI-42(SUVmax 2.6 vs 2.1)。

核心结论

  • [18F]FAPI-42可用于检出Tg或抗Tg抗体生化升高的DTC患者局部复发和转移病灶并反映FAP表达。
  • [18F]FAPI-42 PET/CT在此类患者中的诊断效能与2-[18F]FDG PET/CT相当。

研究设计与样本

  • 共纳入42例Tg或抗Tg抗体生化升高的DTC患者行[18F]FAPI-42 PET/CT,其中11例在7天内另行2-[18F]FDG PET/CT。
  • 图像采用半定量和视觉判读,记录病灶数量、位置和摄取值,评估[18F]FAPI-42 PET/CT诊断能力及影响[18F]FAPI-42摄取的生物标志物。
  • 比较[18F]FAPI-42与2-[18F]FDG的诊断效能和摄取,并分析病灶直径与定量参数的相关性。

主要发现

  • [18F]FAPI-42 PET/CT在27例(64%)患者中检出161个病灶。
  • FAPI阳性局部复发灶摄取值最高,依次为淋巴、其他部位(骨和胸膜)和肺部病灶(平均SUVmax分别为4.7、3.7、3.0、2.2,P < 0.0001)。
  • TSH、Tg和Tg-Ab水平不影响病灶摄取值(中位SUVmax分别为2.4 vs 3.2,P = 0.56;2.9 vs 2.4,P = 0.0935;2.8 vs 2.6,P = 0.0525)。
  • 两种模态均检出的7例患者共90个阳性病灶,所有阳性病灶2-[18F]FDG摄取均统计学高于[18F]FAPI-42(SUVmax 2.6 vs 2.1,P = 0.026)。
  • 局部复发和淋巴病灶中[18F]FAPI-42的SUVmax高于2-[18F]FDG(SUVmax分别为4.2 vs 2.9和3.9 vs 3.4,P > 0.05)。

临床怎么用

  • 作者认为[18F]FAPI-42可用于检出Tg或抗Tg抗体生化升高的DTC患者局部复发和转移病灶并反映FAP表达。
  • 作者认为[18F]FAPI-42 PET/CT在此类患者中的诊断效能与2-[18F]FDG PET/CT相当。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study aimed to assess the diagnostic performance of [18F]FAPI-42 PET/CT and compare it with that of 2-[18F]FDG PET/CT in patients with differentiated thyroid cancer (DTC) with biochemical elevations in Tg or anti-Tg antibodies. METHODS: A total of 42 patients with DTC with biochemical elevations in Tg or anti-Tg antibodies underwent [18F]FAPI-42 PET/CT as part of this study; of which, 11 additionally underwent 2-[18F]FDG PET/CT within 7 days. Images were semi-quantitatively and visually interpreted, and the quantity, location, and uptake values of lesions were noted. The diagnostic capacity of [18F]FAPI-42 PET/CT and biomarkers affecting the uptake of [18F]FAPI-42 were evaluated. In addition, the diagnostic performance and uptake of [18F]FAPI-42 and 2-[18F]FDG were compared, and the correlation between lesion diameter and quantitative parameters was investigated. RESULTS: A total of 161 lesions were detected in 27 (64%) patients on [18F]FAPI-42 PET/CT. FAPI-positive local recurrence showed the highest uptake intensity, followed by lymphatic, other site-associated (bone and pleura), and pulmonary lesions (mean SUVmax, 4.7 versus 3.7 versus 3.0 versus 2.2, respectively; P < 0.0001). The levels of TSH, Tg, and Tg-Ab did not affect the uptake value of lesions (median SUVmax: 2.4 versus 3.2, P = 0.56; 2.9 versus 2.4, P = 0.0935; 2.8 versus 2.6, P = 0.0525, respectively). A total of 90 positive lesions were detected in 7 patients using both modalities. All positive lesions showed statistically higher uptake of 2-[18F]FDG than that of [18F]FAPI-42 (SUVmax, 2.6 versus 2.1; P = 0.026). However, the SUVmax of [18F]FAPI-42 was higher than that of 2-[18F]FDG in local recurrences and lymphatic lesions (SUVmax, 4.2 versus 2.9 and 3.9 versus 3.4, respectively; P > 0.05). CONCLUSION: [18F]FAPI-42 can be used for detecting lesions and reflecting FAP expression during local recurrence and metastasis in patients with DTC with biochemical elevations in Tg or anti-Tg antibodies. The diagnostic performance of [18F]FAPI-42 PET/CT is comparable with that of 2-[18F]FDG PET/CT in such patients.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Mu X, Huang X, Jiang Z, et al. [18F]FAPI-42 PET/CT in differentiated thyroid cancer: diagnostic performance, uptake values, and comparison with 2-[18F]FDG PET/CT. Eur J Nucl Med Mol Imaging. 2022. PMID: 36495325. doi:10.1007/s00259-022-06067-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。